Corbus Pharmaceuticals Reports 2015 Second Quarter Financial Results and Provides Business Update
August 13, 2015 07:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
NORWOOD, MA--(Marketwired - Aug 13, 2015) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, and...
Corbus Pharmaceuticals to Present at the Canaccord Genuity Growth Conference on August 13, 2015
August 06, 2015 07:35 ET
|
Corbus Pharmaceuticals Holdings, Inc.
NORWOOD, MA--(Marketwired - Aug 6, 2015) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, and...
Corbus Pharmaceuticals Announces Call Notice for Exercise of Warrants
July 27, 2015 16:30 ET
|
Corbus Pharmaceuticals Holdings, Inc.
NORWOOD, MA--(Marketwired - Jul 27, 2015) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage pharmaceutical company targeting rare, chronic, and...
Corbus Pharmaceuticals Announces Dosing of First Patient in Phase 2 Clinical Trial of Resunab(TM) for the Treatment of Dermatomyositis
July 13, 2015 08:33 ET
|
Corbus Pharmaceutical Holdings Inc.
NORWOOD, MA--(Marketwired - Jul 13, 2015) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, and...
Corbus Pharmaceuticals to Present at the JMP Securities Life Sciences Conference on June 23, 2015
June 17, 2015 07:05 ET
|
Corbus Pharmaceuticals Holdings Inc.
NORWOOD, MA--(Marketwired - Jun 17, 2015) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic,...
Corbus Pharmaceuticals Announces Inclusion in Russell MicroCap(R) Index
June 16, 2015 07:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
NORWOOD, MA--(Marketwired - Jun 16, 2015) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, and...
Corbus Pharmaceuticals Announces FDA Orphan Drug Designation for Resunab(TM) for the Treatment of Systemic Sclerosis (Scleroderma)
June 12, 2015 08:12 ET
|
Corbus Pharmaceutical Holdings Inc.
NORWOOD, MA--(Marketwired - Jun 12, 2015) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, and...
Corbus Pharmaceuticals Expands Clinical Development of Resunab(TM) With a Phase 2 Trial for the Treatment of Rare Disease Dermatomyositis
June 05, 2015 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
NORWOOD, MA--(Marketwired - Jun 5, 2015) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, and...
Corbus Pharmaceuticals Announces Presentation of Positive Data on Resunab(TM) in Pre-Clinical Models of Cystic Fibrosis at the 2015 Cystic Fibrosis Foundation Research Conference
June 01, 2015 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
NORWOOD, MA--(Marketwired - Jun 1, 2015) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, and...
Corbus Pharmaceuticals Receives FDA Clearance to Initiate Phase 2 Clinical Study of Resunab(TM) for the Treatment of Cystic Fibrosis
May 18, 2015 08:30 ET
|
Corbus Pharmaceuticals Holdings Inc.
NORWOOD, MA--(Marketwired - May 18, 2015) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare,...